Pancreatic Cancer

Pancreatic cancer is a malignant tumor that arises in the pancreas, the gland that produces digestive enzymes and the hormones insulin and glucagon. The great majority of cases are pancreatic ductal adenocarcinoma (PDAC), which develops from the cells lining the pancreatic ducts. Pancreatic neuroendocrine tumors, which arise from the hormone-producing islet cells, are a much rarer and biologically different group. The disease is among the most lethal cancers. Its symptoms are vague and often appear only after it has spread, so most patients present when surgical cure is no longer possible. In the United States, the American Cancer Society estimated about 67,530 new diagnoses and about 52,740 deaths for 2026, and the five-year relative survival rate has stayed near 13%. Globally it ranks among the leading causes of cancer death, and its burden is growing in many countries, which makes it an important subject in oncology, public health, and medicine.

This entry explains what pancreatic cancer is and how it is distributed across populations, then turns to its causes: modifiable exposures such as smoking, obesity, diabetes, and chronic pancreatitis, and inherited syndromes that involve genes such as BRCA1, BRCA2, and CDKN2A. It describes the molecular changes that drive tumor growth, the dense stromal environment that shields the tumor from treatment, and the precursor lesions that may be detected before invasion. The entry then covers clinical presentation, diagnosis, and staging, the state of screening for high-risk people, and the main treatments, including surgery, chemotherapy, radiation, and targeted approaches for selected patients. It ends with prognosis, supportive and palliative care, and the open research questions that shape the field.

Definition and Anatomical Origin

The pancreas is both an exocrine and an endocrine organ, and this dual role determines what kind of cancer can arise in it. The exocrine tissue, made up mainly of acinar cells and the ductal cells that line the drainage network, secretes digestive enzymes into the duodenum. The endocrine tissue sits in the islets of Langerhans, whose alpha and beta cells release glucagon and insulin into the bloodstream to regulate blood glucose. Because each cell type can undergo malignant change, the pancreas gives rise to several distinct tumour families with different biology, treatment and outcomes. The term "pancreatic cancer" on its own usually refers to the exocrine tumours, and in practice it is nearly always a reference to the most common of them.

Pancreatic ductal adenocarcinoma (PDAC) is by far the dominant histological type. Reviews consistently place it at more than 90% of pancreatic cancers, and one review notes that the term "pancreatic cancer" is often treated as synonymous with PDAC unless another type is specified. Its aggressiveness reflects both its tendency to invade locally and its early spread, which is why most patients are not candidates for curative surgery at diagnosis. Detailed genetics, stroma and staging are covered in later sections.

The remaining types are uncommon. Pancreatic neuroendocrine neoplasms form the second-largest group, though published estimates vary: one review gives 3–5% of all cases, while others report 5–8%. Their biology differs markedly from PDAC. Well-differentiated pancreatic neuroendocrine tumours generally follow an indolent course and are more often amenable to surgical resection, whereas poorly differentiated neuroendocrine carcinomas behave more like aggressive carcinomas. Imaging can also distinguish them: in one MRI series, PDAC showed poorly defined borders and more frequent lymph node metastasis than neuroendocrine carcinoma, which tended to enhance more strongly on contrast imaging.

Exocrine tumours other than PDAC include acinar cell carcinoma, which accounts for roughly 1–2% of pancreatic cancers, and solid pseudopapillary neoplasm, which is rare and typically affects young women. Acinar cell carcinoma has morphological and genetic features distinct from PDAC and a more favourable prognosis; in a Korean multicentre series of resected cases, the five-year survival was 57.4%. A German registry analysis found that surgical resection was the strongest positive prognostic factor for this tumour. Mixed tumours also exist, and up to a quarter of acinar carcinomas contain a substantial neuroendocrine or ductal component, which complicates both diagnosis and treatment planning.

Anatomically, the pancreas is divided into the head, body and tail. The head lies within the C-loop of the duodenum and is closely associated with the common bile duct, which passes through it before draining into the duodenum. Most pancreatic cancers arise in the head, with estimates ranging from about 60–70% to the "vast majority," and the remainder in the body or tail. This location determines the early clinical picture. A head tumour can compress the distal common bile duct and block bile flow, producing painless obstructive jaundice that prompts medical attention while the tumour is still relatively small and potentially resectable. Tumours of the body and tail usually do not obstruct the bile duct, so they typically present late with pain and weight loss, and they are more often locally advanced or metastatic at diagnosis. This difference in presentation is one reason why head tumours have been reported to carry a more favourable prognosis, although the magnitude of that difference is debated and depends on tumour stage and treatment received.

Epidemiology and Global Burden

Age and sex distribution

Pancreatic cancer is chiefly a disease of later life. Its incidence rises steeply after middle age, with most cases diagnosed in the sixth to eighth decades. Most diagnoses still occur after age 55, but a JCO Global Oncology analysis expects incidence and mortality in adults aged 49 and younger to climb in the coming decades. Men carry a heavier burden at every level. In the GBD 2017 estimates, 232,000 of the 448,000 incident cases worldwide in 2017 were in males. The GBD 2021 analysis reached the same conclusion, finding higher incidence, mortality, DALY and prevalence rates in males than in females.

The age profile is shifting at the younger end. Registry data for ages 15–39 in the United States show that incidence in young women rose 2.1-fold, from 3.3 to 6.9 per million between 2001 and 2019. Growth is steeper in women: for people under 55, the average annual percentage change was substantially higher in women (2·36%) than in men (0·62%), and the fastest rise was among women aged 15–34. Part of this apparent increase reflects detection rather than a true rise in the disease. A study in Annals of Internal Medicine concluded that much of the growth in young adults comes from identifying small, early-stage endocrine tumours, not from more pancreatic adenocarcinoma, while mortality in this group stayed flat. The rise in incidence among younger adults is primarily attributed to the increased detection of smaller, early-stage tumours. Whether the trend reflects a real change in risk remains under investigation, and the genetic contribution to early-onset disease is still uncertain.

Global incidence, mortality and DALYs

The Global Burden of Disease (GBD) 2021 study estimated that both the global age-standardized incidence rate and the age-standardized mortality rate reached 6.0 per 100,000 population in 2021, with 508,533 new cases and 505,752 deaths. Over the longer span from 1990, the number of cases rose from approximately 207,905 to 508,533, while the age-standardized incidence rate increased from 5.47 to 5.96 per 100,000.

The burden is also measured in disability-adjusted life years (DALYs). DALYs estimate the overall impact of a disease on quality of life. Total DALYs rose from 5.21 million to 11.32 million over the same period. The age-standardized DALY rate changed far less, from 129.32 in 1990 to 130.33 per 100,000 in 2021, which suggests that much of the growth in absolute burden comes from population size and ageing rather than from a sharp rise in risk per person.

Estimates differ between GBD releases. The GBD 2019 study reported 530,297 incident cases and 531,107 deaths in 2019, with an age-standardized incidence rate of 6.6, which is higher than the figure later reported for 2021. These figures should therefore not be compared directly across rounds.

Geographic and socioeconomic variation

Rates are highest in wealthier countries. One analysis of Latin America notes that rates are four- to five-fold higher in higher-HDI countries, with the highest incidence rates in Europe, Northern America and Australia/New Zealand. The GBD 2017 analysis found that the age-standardised death rate was highest in the high-income super-region across all years from 1990 to 2017.

Growth, however, is concentrated elsewhere. The fastest increases in both incidence and mortality rates have occurred predominantly in low-to-middle sociodemographic index regions. Africa shows the fastest growth of any continent, which one analysis attributes to a critical lack of effective policies and investments in prevention, early detection, and treatment services.

Behavioural and metabolic factors account for a substantial share of deaths. In 2019, the proportion of deaths attributable to smoking was 21.4%, to elevated fasting glucose 9.1%, and to high BMI 6%. Deaths linked to metabolic risks rose 3.5-fold, from 22,091 in 1990 to 77,215 in 2019. Access to care also appears in the data: countries with high healthcare access quality had much higher age-standardized DALY rates. This pattern may partly reflect better case ascertainment in well-resourced health systems, though the source does not establish that explanation. Differences in socioeconomic conditions and public health infrastructure therefore shape both observed rates and the reliability of the numbers.

Projections and drivers of future burden

The GBD 2021 analysis used a Bayesian age-period-cohort model to project future trends until 2050. Its rate projections are optimistic: the age-standardized incidence and mortality rates are expected to decline significantly, while the age-standardized DALY rate is anticipated to keep a steady downward trend by 2050. Other analyses expect the opposite for absolute numbers. Earlier GBD-based work argued that the increase in incidence is likely to continue as the population ages. A more recent analysis projects an 85–91% increase in elderly pancreatic cancer cases by 2050, with Asia facing the greatest challenge. The projected Asian burden is linked to its large ageing population and rising prevalence of metabolic disorders such as diabetes. In Europe, the EU-28 projection estimates 142,765 incident cases and 138,080 deaths by 2050, with only modest increases in age-standardized rates.

Metabolic risk is also projected to matter more for younger patients. In people aged 15–49, deaths attributable to high fasting glucose reached 3,334 cases in 2021, 2.3 times higher than in 1990. These projections depend on the assumptions of each model, and diabetes prevalence, body weight trends, and tobacco control will shape the eventual outcome.

Risk Factors and Modifiable Exposures

Tobacco smoking

Among the exposures that people can change, cigarette smoking has the most consistent evidence behind it. In the pooled analysis of the International Pancreatic Cancer Case-Control Consortium, current cigarette smoking was associated with a twofold increased risk of pancreatic cancer, and the risk increased with the number of cigarettes smoked and the duration of smoking. Risk rose with years of smoking up to 40 years. A larger earlier meta-analysis of 82 cohort and case–control studies published between 1950 and 2007 reported a summary relative risk of 1.7.

The excess risk is partly reversible. A 2018 meta-analysis found that pancreatic cancer risk sharply increases with a low number of cigarettes or after a few years of smoking and that it rapidly decreases a few years after cessation, although it takes almost 20 years to reach that of never smokers. In the UK Biobank cohort of nearly 493,000 participants, compared with current smokers, ex-smokers had reduced odds for AP, CP, and PC, with an adjusted odds ratio of 0.62 for pancreatic cancer. Exposure from cigars, pipes, and passive smoke appears to matter less: in a San Francisco Bay Area population study, cigar and pipe smoking and exposure to passive smoke were not associated with pancreatic cancer. Smoking-attributable fractions are substantial; one estimate holds that 25-30% of pancreatic cancer cases in the United States are related to cigarette smoking.

Obesity, diabetes, and diet

Obesity shows a weaker association than smoking. A 2003 meta-analysis of six case–control and eight cohort studies involving 6391 cases estimated that the estimated per unit increase in body mass index would translate into a relative risk of 1.19 for obese people compared to people with a normal body weight. The authors also cautioned that the small magnitude of the summary risk means the possibility of confounding cannot be excluded.

Diabetes has a stronger link, but its causal direction is debated. One meta-analysis of cohort studies reported that DM was associated with an increased risk of PaC (the summary RRs=1.94; 95% CI, 1.66-2.27), with significant evidence of heterogeneity among these studies, and the authors noted that whether DM is a cause or a consequence of PaC is still controversial. Timing matters: according to one review table, less than 0.3–0.8% of patients with new-onset diabetes develop pancreatic ductal adenocarcinoma within 3 years of diabetes diagnosis, while longer-standing diabetes carries a 1.5–2-fold increase. Prediabetes is also implicated: a recent cohort meta-analysis found a higher incidence of pancreatic cancer in those with prediabetes compared to people with normoglycemia, with a risk ratio of 1.42.

Diet is harder to pin down. An umbrella review concluded that pancreatic cancer risk was more consistently associated with systemic metabolic dysfunction, particularly impaired glucose regulation, diabetes, metabolic syndrome, and abdominal adiposity, than with the related dietary exposures examined. Overall, related dietary exposures generally showed weaker and less consistent associations, with no exposure supported by convincing evidence. Some studies have suggested a role for sugary drinks, though more research is needed to confirm this link. Smoking and diabetes also interact: a pooled analysis reported that effect modification by family history of pancreatic cancer and diabetes was likely.

Chronic pancreatitis and gallstones

Long-standing inflammation of the pancreas is one of the better-established non-genetic routes to cancer. Excess alcohol use is the most common cause of chronic pancreatitis. Gallstones are proven to also cause pancreatitis. Estimates for alcohol-related disease suggest that during alcoholic chronic pancreatitis, the cumulative risk of cancer is estimated at 4% after 15 to 20 years. The proposed mechanism is that inflammatory cells release growth factors and toxins, which over many years can damage DNA and drive uncontrolled cell growth (see inflammation). Smoking adds to this pathway, since tobacco is another co-factor.

Gallstones are associated with a raised risk as well, though part of this may be an artifact of diagnosis. Researchers have suggested that gallstones can cause chronic pancreatitis, but also that the increased risk may only be for a short time after gallstones have been diagnosed. This could be because people have a number of tests when they are diagnosed with gallstones. So, if there is a pancreatic cancer, the doctor may find it at the same time. Most people with chronic pancreatitis never develop cancer, so the condition marks a higher-risk group rather than a certain outcome. Hereditary forms of pancreatitis, which carry much higher risks, are discussed under genetics.

Occupational and environmental exposures

Occupational and environmental exposures, including certain pesticides, solvents, and other industrial chemicals, have been investigated as possible causes. For most of these, the evidence is weaker and less consistent than for smoking, metabolic disease, or chronic pancreatitis. Associations reported in individual occupational studies have often been small, based on limited exposure assessment, or unconfirmed in larger analyses, so the strength of evidence differs substantially from one agent to another. Current risk assessments therefore rely mainly on the established factors above, and specific chemical links remain an area of ongoing study within epidemiology.

Hereditary Predisposition and Genetic Syndromes

Estimates of how many pancreatic cancers have a hereditary basis depend on how "hereditary" is defined. One review puts approximately 10% to 15% of PDAC cases on a hereditary or familial footing. A narrower figure counts only cases that carry an identifiable syndrome-causing gene, which one source gives as 5-10% of cases. Other summaries describe about 7% of patients with a detectable inherited germline mutation, plus a further 5% with a strong family history but no mutation found. Because the figure for detectable germline variants keeps rising, guidance has changed. Clinicians have recommended genetic testing for all patients diagnosed with PDAC since 2019, since age and family history alone miss many carriers. Among patients diagnosed before 60, one review reports germline pathogenic variants in 21.2% of cases.

Family History Criteria

The most common clinical threshold is familial pancreatic cancer, defined as at least two first-degree relatives affected by PDAC without an identifiable hereditary syndrome. Risk rises steeply with the number of affected relatives. One prospective registry found that a single affected first-degree relative raised risk two- to fivefold, and two relatives raised it about 6.4-fold, with early onset in the family carrying further risk. The consensus threshold for high-risk status is a lifetime risk greater than 5%, or a five-fold increased relative risk, compared with a general-population lifetime risk of roughly 1.3–1.5%. Assessment usually begins with a three-generation pedigree recording tumour types and ages at diagnosis. Features that point to an inherited cause include an early age of onset, multiple affected relatives, and multiple primary tumours. Ancestry matters too: individuals of Ashkenazi Jewish ancestry have a higher population frequency of BRCA1/2 mutations.

BRCA1, BRCA2, PALB2, and ATM

BRCA2 is the most frequently identified gene. In familial kindreds, BRCA2 variants account for 5%–17% of familial pancreas cancer kindreds, with a relative risk of 3.5–6.2. Germline BRCA1 or BRCA2 variants are found in 5%–9% of patients with pancreatic cancer. These genes participate in homologous recombination and double-stranded DNA break repair, and the PALB2 protein works with both BRCA1 and BRCA2 in that process. PALB2 is rarer: about 1-3% of patients with familial pancreatic cancer carry an inherited variant, and PALB2 variants also raise breast cancer risk. ATM variants are associated with a monoallelic relative risk and cumulative lifetime risk that has been estimated to be 4.5%–9.5% for relative risk and 5%–14% for cumulative lifetime risk. Biallelic ATM variants instead cause the rare neurological condition ataxia telangiectasia.

CDKN2A, STK11, and Other High-Risk Syndromes

CDKN2A germline variants cause familial atypical multiple mole melanoma (FAMMM) syndrome. Carriers have a 15-35% lifetime risk of developing pancreatic cancer, although the variant itself is rare in families, and in one series of 521 patients meeting familial criteria only 2.5% carried a CDKN2A mutation. Peutz–Jeghers syndrome, caused by STK11 variants, carries the highest absolute risk of any hereditary syndrome, with a 11%–36% lifetime risk of pancreatic cancer. Guidance from the American Gastroenterological Association recommends considering pancreatic surveillance for carriers of CDKN2A variants and for those with BRCA1, BRCA2, PALB2, or ATM mutations who have affected first-degree relatives.

Lynch Syndrome and Hereditary Pancreatitis

Lynch syndrome arises from germline variants in DNA mismatch repair genes such as MLH1, MSH2, and MSH6. Its pancreatic risk is modest compared with its colorectal and endometrial risk. Published figures place the relative risk for pancreatic cancer at 8.6, with a lifetime risk of about 3.7%. A recent nationwide Dutch cohort estimated a combined lifetime risk of pancreatic ductal adenocarcinoma and related tumours of 0 to 3.4% across different genes, below the 5% threshold, and it questioned whether current surveillance recommendations for Lynch carriers are justified.

Hereditary pancreatitis is a separate, rare route, most often linked to PRSS1 variants that increase trypsin activation within the gland. Symptoms typically begin in childhood and recur repeatedly. Reported lifetime pancreatic cancer risks in these families range widely, from 7.2% to 53.3%, and earlier estimates for PRSS1 carriers approach 40%.

Genetic Testing, Counselling, and Disclosure

A positive result is only useful if it can be interpreted and changes management. Multigene panels often reveal variants of uncertain significance whose meaning is not yet defined, so counselling is needed before and after testing. Testing also raises questions about informing relatives. A result for one patient can imply risk for blood relatives, who may choose whether to be tested and monitored. Ethical practice therefore requires informed consent that addresses what will be shared, with whom, and how the patient's privacy will be protected, as well as support for families who do not wish to learn of their risk. These questions are not yet fully settled across health systems.

Molecular Biology and Tumor Microenvironment

From precursor lesions to invasive carcinoma

Most pancreatic ductal adenocarcinomas (PDAC) are thought to develop through a stepwise sequence. The best-characterized precursor is pancreatic intraepithelial neoplasia (PanIN), a microscopic duct lesion graded from low to high. Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are larger cystic lesions with a different histology. Different known precursors appear to arise from different cell types, and for most of them the initiating event is still unclear.

Genetic changes accumulate in a fairly consistent order. In a review of PanIN and IPMN, KRAS mutation and p16/CDKN2A inactivation were early events whose frequency rose with dysplasia grade, while TP53 mutation and SMAD4/DPC4 inactivation were late events, typically seen in high-grade PanIN or in carcinomatous change. The same pattern holds for MCNs, where TP53 mutation and SMAD4/DPC4 inactivation are evident only in the carcinoma. One study reported TP53 mutations in 9.1% of intermediate-grade IPMNs, 17.8% of PanIN-2, 47.6% of PanIN-3 and 75% of invasive ductal adenocarcinomas, which fits a gradual rise in TP53 involvement as lesions progress.

Mouse models support the idea that oncogenic KRAS starts the process but does not finish it. Conditional expression of Kras G12D in pancreatic progenitor cells was enough to form PanIN lesions, which had long latencies and low penetrance of invasive disease. When mutant Kras was combined with loss of Trp53, Ink4a/Arf, or Smad4, PanIN progression became rapid and invasive, highly metastatic PDAC developed in nearly all animals.

Driver alterations and growth signaling

KRAS is the most frequently altered driver. Oncogenic KRAS mutations are detected in more than 90% of low-grade PanIN lesions, which supports its role as an early step. Because KRAS mutations, although initial in most cases, are not sufficient to promote invasive disease, the later tumor suppressor losses are needed to remove the brakes on growth.

Reported frequencies vary between studies. One review gives KRAS in 88%, TP53 in 77%, SMAD4 in 29%, CDKN2A in 18% and TGFBR2 in 7% of cases, whereas another reports CDKN2A, TP53 and SMAD4 altered in 90%, 75% and 50% of tumors. The differences likely reflect cohort composition and detection methods. A small minority of tumors (5–10% of pancreatic cancers) lack the common mutations altogether.

CDKN2A encodes p16INK4A, a regulator of the G1 checkpoint of the cell cycle, and its loss can occur by deletion or by promoter hypermethylation, which links the lesion to epigenetic silencing. TP53 normally restrains transformation, and its inactivation removes that control. SMAD4 (DPC4) mediates TGF-β signaling; one series found homozygous deletion of DPC4 in 32% of cases, which would shut down a pathway that otherwise limits proliferation.

The desmoplastic stroma and immunosuppressive niche

PDAC is characterized by an abundant, fibrous stroma. Classical PDAC cells are usually embedded in a diverse desmoplastic stroma, containing extracellular matrix, cancer-associated fibroblasts (CAFs), endothelial cells, pericytes, nerves and immune cells. The stroma is not passive: it is recognized as a critical mediator of disease progression, acting both directly on cancer cells and indirectly on the tumor immune microenvironment.

The microenvironment is also immunosuppressive. Myeloid-derived suppressor cells, regulatory T cells and tumor-associated macrophages are prominent in the tumor microenvironment. Stromal composition differs by tumor subtype: in one single-cell analysis, basal-like patient stroma showed higher expression of CCL18, a chemokine linked to increased regulatory T cells and M2-like macrophages. The dense matrix and vasculature are generally thought to impede drug penetration and immune cell infiltration, which helps explain why immunotherapies that have benefited many cancers have not shown comparable benefit in PDAC.

Tumor heterogeneity and molecular subtypes

Several transcriptional classifications have been proposed, and they do not fully agree. Collisson and colleagues first described three subtypes: classical, quasimesenchymal and exocrine-like. Moffitt and colleagues used tumor and stromal signals to describe the basal-like and classical tumor subtypes, while Bailey and colleagues proposed four subtypes: squamous, immunogenic, pancreatic progenitor, and aberrantly differentiated endocrine exocrine. Puleo and colleagues later refined the scheme into five subtypes: pure basal-like, stroma-activated, desmoplastic, pure classical and immune classical.

The basal-like program is the most consistently adverse. The basal-like (or squamous) subtype carries a worse prognosis than the classical subtype, and in the Puleo cohort the basal-like subtype had the worst overall survival, with a median of 10.3 months. Classical tumors retain glandular features and express endodermal lineage-specifying factors such as GATA6. Mechanistically, one study linked SERPINB3 upregulation in basal-like/squamous PDAC to reduced survival, and expression of SERPINB3 enhanced invasion in vitro and promoted lung metastasis in a mouse xenograft model.

Subtype labels are also sensitive to how much tumor cell content a sample contains. Puleo and colleagues addressed the problem of variable neoplastic cell levels in tumor samples and the influence of stromal cells, which is a reminder that bulk profiles mix tumor and stroma. Newer single-nucleus and spatial approaches describe three multicellular communities, classical, squamoid-basaloid and treatment-enriched. Whether any of these schemes can reliably guide therapy choice remains under investigation rather than established in routine practice.

Clinical Presentation, Diagnosis, and Staging

Symptoms and clinical course

Pancreatic cancer seldom causes noticeable problems early. Cancer in the pancreas does not cause symptoms in the early stages, but it can create nonspecific symptoms as it grows and spreads. Because these complaints overlap with many other conditions, pancreatic cancer is often not diagnosed until it is advanced.

The symptom pattern depends largely on tumor location. A lesion in the head of the gland can compress the distal common bile duct, which runs through this region. Bile then backs up, and painless jaundice often becomes the first clear sign. Jaundice occurs when the tumor grows and obstructs the common bile duct, which runs partially through the head of the pancreas. Jaundice also darkens urine and lightens stool, because bilirubin leaves the body through the kidneys rather than the bowel. You pass it out in your urine (making it look dark) rather than through the bowel (so your stools looks lighter). Jaundice from a tumor is not always accompanied by pain, and many other causes, such as gallstones and hepatitis, are far more common.

Tumors of the body or tail tend to grow large before they are noticed and press on neighboring structures. A tumor that forms in the body or tail of the pancreas can grow fairly large and begin to press on nearby organs, which can cause abdominal pain. If nerves in the retroperitoneum are involved, the pain may radiate to the back. Weight loss is another frequent feature. It can result from inflammatory proteins secreted by the cancer, jaundice, pain or other symptoms, and physical obstructions in the gastrointestinal tract. Clinicians often treat a rapid loss of about 5% of body weight within a month as a red flag. New-onset hyperglycaemia, fatigue, nausea, and venous thrombosis can also appear, the last of which may present as swelling in a limb.

Imaging and tissue confirmation

Suspicion usually leads to cross-sectional imaging. A pancreas-protocol CT uses thin slices and several contrast phases; optimal multi-phase technique including a non-contrast phase plus arterial, pancreatic parenchymal and portal venous phase of contrast enhancement with thin cuts (3mm) throughout the abdomen is preferred. For local staging, CT and MRI are equivalent for local staging. Endoscopic ultrasound provides high-resolution views of the pancreas and allows fine-needle aspiration or core biopsy of masses that are hard to see on other modalities. Histological confirmation is generally required before most neoadjuvant treatment, because benign inflammatory masses and other neoplasms can mimic the cancer on imaging.

Serum markers and their limits

CA19-9, a sialylated carbohydrate antigen, is the serum marker in widest clinical use. CA19-9 is currently the only FDA-approved serum biomarker widely used for pancreatic cancer management, with clinical application limited to monitoring treatment response and detecting recurrence. Its weaknesses are substantial. Individuals who lack the Lewis enzyme cannot synthesize the antigen, so CA 19-9 serum level evaluation in pancreatic cancer patients is limited by poor sensitivity, false negative results in Lewis negative phenotype (5-10%) and increased false positivity in the presence of obstructive jaundice (10-60%). In symptomatic patients, diagnostic sensitivity and specificity are roughly 79–81% and 82–90%, respectively, and routine usage of CA19-9 as a screening tool for PC among general public is ineffective and results in a low positive predictive value due to the relatively low incidence of PC in the general population.

The marker has more value once cancer is established. Preoperative levels below 37 U/mL have been associated with longer median survival than higher levels, and a CA 19-9 serum level of < 100 U/ml implies likely resectable disease whereas levels > 100 U/ml suggest unresectablity or metastatic disease. Serial measurements after surgery or chemotherapy are used to track response, but a rising or non-normalizing value must always be read alongside imaging, and obstructive jaundice itself can distort the result.

Staging and resectability categories

The TNM system classifies the primary tumor (T), regional lymph nodes (N), and distant metastasis (M). Tumor size and the involvement of major arteries such as the celiac axis and superior mesenteric artery are central to the T category. Staging then feeds into a clinical grouping that determines treatment. In the absence of distant metastases, PDAC is classified into three main categories: resectable, borderline resectable, and locally advanced or un-resectable. Metastatic disease, usually in the liver, peritoneum, or lungs, is treated as a separate category. The exclusion of liver metastases is an indispensable condition for defining borderline resectable pancreatic cancer.

Borderline status depends on how the tumor contacts vessels. Technically, borderline tumors are those tumors that involve vessels to a limited extent considering that vein involvement has a less effect on the results of resection compared to arterial vessels. The criteria are not universal. In the AHPBA/SSAT/SSO definition, all tumors with any degree of abutment or encasement of the SMV-PV are considered borderline resectable. In contrast, the NCCN definition requires distortion of the SMV-PV for the tumor to be considered borderline resectable. A tumor may therefore be classified differently depending on the guideline applied, which is why multidisciplinary review of imaging is essential before treatment decisions are made.

Screening, Surveillance, and Early Detection

Why there is no population-wide screening

No national or international body recommends screening the general population for pancreatic cancer. The main reason is arithmetic. The lifetime risk is relatively low, at roughly 1.5 percent, and current screening tools have a low positive predictive value when applied to low-risk populations. In such a group, most positive results would be false alarms that lead to unnecessary imaging, biopsies, and operations. Precursor lesions are also common and most never progress, so a test that flags them would detect many lesions that will not become cancer. Early-stage disease itself is hard to find, because it rarely causes symptoms and is small on imaging.

Surveillance for high-risk groups

Surveillance is instead offered to people whose risk is substantially raised. Current frameworks commonly use an estimated absolute lifetime risk of approximately 5% or greater, compared with approximately 1.5% in the general population. In practice, eligible groups include carriers of pathogenic germline variants, people from families with hereditary cancer syndromes, and people with a strong family history of the disease.

The guidelines differ in their details. The CAPS and AGA frameworks recommend surveillance for people with BRCA-associated risk who have at least one affected first-degree relative, whereas the ASGE guidelines suggest that all BRCA1/2 mutational carriers should undergo screening for pancreatic cancer. Starting ages also vary. The AGA position is that annual surveillance is typically started at age 50 or 10 years younger than the youngest affected relative. For hereditary pancreatitis, surveillance is typically recommended from 40 years of age or 20 years after the first episode of pancreatitis. Some clinicians have proposed tighter intervals for specific genes; for example, CDKN2A carriers should undergo more frequent surveillance, e.g., every 6 months, because this group may have a more aggressive course.

Surveillance relies mainly on imaging. Intermittent longitudinal imaging, including magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP), and/or endoscopic ultrasound (EUS) is suggested. CT is generally reserved for patients who cannot undergo MRI or EUS, partly because of cumulative radiation. Programs are usually run in specialized centers. Even so, yield remains limited: one Dutch familial cohort reported that only 60% of the pancreatic cancers found were resectable, and the authors of later reviews note that finding resectable lesions in time is still a challenge.

Pancreatic cysts

Cysts are a separate and more common issue. Their progression to invasive cancer is slow, on the order of 0.2% per year, so the central task is sorting out the small fraction that needs treatment. Guidelines rely on "high-risk stigmata" and "worrisome features." Stigmata carry the greatest risk, and the probability of malignancy rises with each additional worrisome feature, from 22%, 34%, or 59% with 1, 2, and 3 worrisome features respectively. Clinical and laboratory markers also matter. High-risk clinical and laboratory features include obstructive jaundice, recurrent pancreatitis, elevated serum carbohydrate antigen 19-9, presence of cells demonstrating high-grade dysplasia or neoplasia, and new-onset or worsening diabetes.

Management follows these features. MRCP with dynamic MRI is the test of choice for diagnosis and assessment of high-risk or worrisome characteristics, and cysts with high-risk features, as well as main duct IPMNs and solid pseudopapillary tumors, should be referred for surgical excision. Cysts without these features are followed, with intervals that might range from 3 months to 2 years. The 2024 International Association of Pancreatology guidelines updated the list of worrisome features, adding new onset or acute exacerbation of diabetes mellitus within the past year and cystic growth rate ≥ 2.5 mm/year. The evidence base remains weak: one review notes that these guidelines are based on low-quality data and primarily represent expert opinion, and validation studies have found considerable variations in sensitivity, specificity, and predictive values across frameworks.

Biomarkers and artificial intelligence

The only blood marker in routine clinical use is CA19-9, and its performance is modest. One review cites relatively low sensitivity (79%) and specificity (82%), which is why it is interpreted alongside imaging rather than used alone.

Circulating tumor DNA (cell-free DNA released into the circulatory system by tumor cells undergoing apoptosis and necrosis) is the most studied candidate. Methylation-based panels have shown strong numbers in single studies: one 17-gene panel distinguished patients with chronic pancreatitis from those with PDAC with a sensitivity of 91.2% and specificity of 90.8%. However, earlier cell-free DNA studies were often small, with sample sizes of 30 to 90, and many had low sensitivity. Combining genetic and protein markers has shown better results; in one study the combined assay detected 64% of these cancers among patients without distant metastasis. More recent case-control models report high area-under-curve values, but case-control designs select clearly affected patients and healthy controls, which tends to overstate accuracy in a screening population. Blood tests therefore remain investigational for early detection. Their more established role is after surgery: in a small tumor-informed study, a positive postoperative ctDNA status was significantly associated with a higher risk of recurrence and poorer survival, although such results still require larger trials.

Artificial intelligence tools have been trained on CT and MRI to flag suspicious pancreatic lesions and to estimate the malignancy risk of cysts. Most published work is retrospective and single-center, and prospective multicenter validation is limited. AI-based tools are not part of current surveillance recommendations, which still rest on imaging interpreted by specialists.

Treatment Modalities

Treatment planning starts with whether the tumor can be removed completely, and then considers how fit the patient is for surgery or chemotherapy. Surgery, systemic therapy, and radiation are usually sequenced rather than used as alternatives, and the staging categories described elsewhere determine where each fits.

Surgical resection and perioperative therapy

Pancreaticoduodenectomy (the Whipple procedure) removes the pancreatic head, the duodenum, the gallbladder, and the lower bile duct, and then reconnects the bile duct, pancreatic duct, and intestine. Its main complications are postoperative pancreatic fistula, delayed gastric emptying, bleeding, and infection, and outcomes are generally better at high-volume centers. Resection is the only route to a realistic cure, but it is often followed by systemic therapy. In the ESPAC-1 trial, six months of fluorouracil after resection raised five-year survival to about 21%, compared with 8% in patients who received no adjuvant treatment. The ESPAC-1 trial showed benefit for the addition of chemotherapy for patients treated with resection using 6 months of fluorouracil. These patients had a 5-year survival rate of 21 vs. 8% in those who did not receive adjuvant therapy. A large share of patients never complete this phase: a significant proportion of patients are unable to initiate adjuvant chemotherapy following pancreatectomy, frequently because of postoperative complications or rapid disease recurrence.

This problem motivated neoadjuvant treatment, given before the operation. A 2020 meta-analysis pooled six randomized trials with 850 patients, all using gemcitabine-based regimens, and found better overall survival with neoadjuvant treatment (hazard ratio 0.73). The benefit held for both chemotherapy alone and chemoradiation. One randomized trial of gemcitabine-based chemoradiotherapy followed by surgery reported a median survival of 17.1 months, compared with 13.5 months for upfront surgery, and an R0 resection rate of 65% against 31%. Trials of multi-agent regimens such as FOLFIRINOX in the neoadjuvant setting are ongoing, and the PREOPANC-2 trial compares them directly with chemoradiation.

Chemotherapy for advanced disease

For metastatic disease, the two standard first-line options are the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) and gemcitabine combined with nab-paclitaxel (GNP). A systematic review found that only these two regimens have shown clinically significant survival benefit over gemcitabine alone in metastatic disease. Head-to-head comparisons have not produced a clear winner for overall survival. A meta-analysis of nine studies with 1,463 FOLFIRINOX patients and 1,527 GNP patients found no significant difference (hazard ratio 1.00). The randomized phase II PASS-01 trial found that a modified FOLFIRINOX gave similar progression-free survival to GNP but with less toxicity, while its per-protocol overall survival favored GNP (hazard ratio 1.59). Real-world studies also disagree. A single-center Indian retrospective series reported superior overall survival with FOLFIRINOX in borderline resectable disease, but also more grade 3 or higher toxicity (45% against 21%). Some other cohorts reported more hematologic toxicity with GNP.

Choice therefore depends largely on fitness, measured by performance status, organ function, and tolerance of toxicity. FOLFIRINOX is usually reserved for patients with good performance status, while GNP is often preferred for patients who are less fit or who cannot tolerate the intensity of the four-drug regimen. Eligibility criteria in current trials reflect this, as in PREOPANC-2, which requires a WHO performance score of 0 or 1.

Radiation therapy

Radiation is used mainly alongside chemotherapy rather than alone. Multimodality therapy combining pancreaticoduodenectomy with postoperative adjuvant chemotherapy (fluorouracil) and external-beam radiation therapy has been reported to improve local control and survival compared with surgery alone, although the sequencing of radiation and its contribution relative to modern chemotherapy remain debated. In locally advanced disease, where the tumor encases major blood vessels but has not spread, chemoradiation is one option, and it is also tested before surgery in borderline resectable cases. Stereotactic body radiotherapy, which delivers highly focused high doses over a few sessions, is increasingly used in locally advanced disease, but its role is supported mainly by retrospective and small prospective studies. Radiation to the pancreas must balance tumor control against injury to the nearby duodenum, bowel, kidney, and liver, and it is also used for palliation of pain or bleeding.

Targeted and biomarker-directed therapy

The clearest biomarker-driven success is the PARP inhibitor olaparib in tumors with germline BRCA mutations. In the POLO trial, of 3,315 patients with pancreatic cancer screened, 247, or 7.5%, had germline BRCA mutations. Among the 154 patients who had not progressed on platinum-based chemotherapy and were randomized, maintenance olaparib improved median progression-free survival to 7.4 months from 3.8 months with placebo (hazard ratio 0.53). However, the final overall survival analysis showed no significant difference between the maintenance olaparib group vs the placebo group, although long-term survival was more common in the olaparib arm. Olaparib has been approved by regulators in the United States, Europe, and Japan for this setting. Its benefit in other homologous recombination-deficient tumors remains unproven; a single case report of ATM and BRIP1 co-mutations describes a remission but cannot establish efficacy.

Immunotherapy helps only a small subset of patients. Immune checkpoint inhibitors such as pembrolizumab are approved across tumor types for tumors with mismatch repair deficiency or high microsatellite instability, but these features occur in only about 1% of pancreatic cancers. Most tumors are immunologically cold because of the dense stroma and immunosuppressive microenvironment described elsewhere. Drugs that target specific KRAS variants, such as KRAS G12C inhibitors, are also limited to small biomarker-defined groups.

Prognosis, Survival, and Supportive Care

Stage-specific survival and the low overall figure

Survival in pancreatic cancer depends heavily on how far the disease has spread at diagnosis. Using data from the U.S. Surveillance, Epidemiology, and End Results (SEER) program for people diagnosed between 2015 and 2021, the five-year relative survival rate is about 44% for localized disease, 17% for regional spread, and 3% for distant metastasis. Across all stages combined, it is about 13%. Relative survival compares patients with the general population, so it is not the same as the share of patients who are alive at five years. Survival also tracks the stage at which resection becomes possible. Some selected early-stage cohorts show far better results: one 2020 study reported five-year survival above 80% for the smallest tumors (stage IA). The overall figure stays low because most patients present when the tumor has already spread or invades major vessels, which rules out surgery. Population-level gains have been modest. Median overall survival in U.S. SEER data rose from about 4 months to 7 months across the decades from 1981 to 2010, yet long-term survival remained very low.

Palliation of pain and obstruction

For patients with unresectable disease, the main goals are to relieve symptoms and preserve eating and mobility. Pain is usually managed with a graded analgesic approach that may include opioids and, in selected cases, a celiac plexus block or neurolysis, which targets the nerve network around the upper abdomen. Obstruction is the second major problem. Tumors in the pancreatic head often compress the distal bile duct, causing jaundice, and the duodenum, causing vomiting and early satiety. Endoscopic biliary stenting, either with plastic prostheses or self-expanding metal stents, is the usual first-line treatment for biliary obstruction, and reported technical success rates exceed 90% with low morbidity. Duodenal obstruction, which affects a smaller share of patients than biliary obstruction, is commonly treated with self-expanding duodenal stents, although stent patency is limited, and in one series the median duration was under six months. Stent placement in the descending duodenum can itself compress the papilla and provoke biliary obstruction or pancreatitis. When endoscopic options fail, laparoscopic gastrojejunostomy or surgical bypass remains an alternative. Comparative studies generally favor the endoscopic approach for quality of life and cost.

Exocrine insufficiency and diabetes

Pancreatic resection and advanced disease both reduce the organ's ability to secrete digestive enzymes and insulin. Exocrine insufficiency is common after pancreatic surgery, and the pancreas has a large functional reserve, so symptoms usually appear only after most of its capacity is lost. Pancreatic enzyme replacement therapy is the standard treatment, typically taken with meals, and the required dose varies between individuals. In practice, dosing is often inadequate: in a Northern European patient survey, many patients on enzymes still reported steatorrhea-related symptoms, and only a third had seen a dietitian. Nutritional counseling, attention to fat-soluble vitamin status, and weight monitoring are therefore central to supportive care. Diabetes after surgery, sometimes called pancreatogenic or type 3c diabetes, develops in roughly 12–20% of patients after pancreaticoduodenectomy. In a single cohort, new-onset diabetes appeared in about 18% of patients without prior diabetes. Insulin is the mainstay of treatment, and total pancreatectomy leaves patients dependent on both insulin and enzymes. Because of the risk of hypoglycemia when intake is reduced, glucose targets in advanced disease are usually individualized.

Quality of life, psychological support, and palliative care

Quality of life is a core outcome for most patients, since treatment decisions often balance survival gains against symptom burden and toxicity. Multidisciplinary teams commonly include surgeons, oncologists, gastroenterologists, dietitians, and social workers, along with specialists in pain and palliative medicine. Palliative care is not limited to end-of-life care; it can run alongside active treatment, addressing pain, nausea, fatigue, and emotional distress from diagnosis onward. Patients and caregivers often face anxiety, depression, and financial strain, and psychological support, including counseling and peer groups, is recommended as part of routine care. Discussions about goals of care, advance directives, and the likely course of illness are typically introduced earlier in the disease course, so that treatment choices reflect the patient's priorities.

Research Directions, Disparities, and Unresolved Questions

From clinical description to molecular classification

Early work on pancreatic tumors was shaped mainly by surgery and pathology. Operations for cancer of the pancreatic head, the duodenum, and the ampulla were attempted in the early twentieth century, and Allen Whipple and colleagues described a staged resection in 1935, which laid the groundwork for the pancreaticoduodenectomy used today. Over the following decades, pathologists increasingly recognized that most malignant pancreatic tumors arise from the ductal epithelium rather than from the endocrine islets, which is why ductal adenocarcinoma became the reference form of the disease. The genomic era began with systematic sequencing of tumor samples. Jones and colleagues (2008) mapped core signaling pathways in human tumors, and a 2012 study by Biankin and colleagues sequenced a large cohort of cases and showed that a small set of genes, including KRAS, TP53, CDKN2A, and SMAD4, recurs across most tumors. These findings reframed the disease from a single entity with variable prognosis into a group of molecularly distinct tumors, a shift that underlies the current push for biomarker-guided treatment.

Drug resistance and the stromal barrier

Resistance is not explained by tumor cells alone. The PC stroma alone accounts for 50 to 80% of the cancer's volume and shapes its architecture, and the dense matrix creates physical barriers. Extremely high interstitial fluid pressures and a dense extracellular matrix combine to limit the delivery and distribution of therapeutic agents. Stromal cells also contribute chemical resistance. Some evidence indicates that cancer-associated fibroblasts might confer resistance to gemcitabine via expression of enzymes involved in the inactivation and degradation of the molecule itself. In addition, CD8+ T cells confined to the stromal periphery by CAF-driven chemokines, immunosuppressive myeloid cells, Tregs, and polarized macrophages limit immune attack, and hypoxia stabilizes HIF-1α and promotes transcriptional programs that enhance glycolysis, angiogenic signaling, epithelial plasticity, invasion, and resistance to therapy.

Strategies to break this barrier have shifted over time. Depleting the stroma with hedgehog pathway inhibitors improved drug penetration in mouse models, but these agents did not translate into survival benefit in patients. Newer approaches aim to reprogram rather than destroy stroma; for example, JAK inhibitors have been used to shift the iCAF subtype towards a myCAF phenotype in experimental settings. Nanocarriers are also being tested, including intelligent, stimuli-responsive nanocarriers, including pH-sensitive, redox-sensitive, and enzyme-activated systems that enable spatiotemporally controlled drug release. Combination designs are the most common response; one study reported that combined with oncolytic virus and immune checkpoint inhibitors, this intervention modulated the TME into a more immune-active state. Reviewers nonetheless note that despite the reported preclinical success of these approaches, no substantial progress has been made clinically.

Disparities in access to surgery and care

Access to potentially curative treatment varies sharply by insurance status. In a National Cancer Database analysis of patients with stage 1 or 2 disease, only 46% of patients underwent surgical resection. By MV analysis, uninsured and those with Medicaid or military were less likely to undergo resection compared to Private and Medicare. Outcomes follow the same gradient. In one national cohort, the 5-year survival of non-Medicaid patients (8.13%, 274 days) was significantly higher than that of Medicaid patients (4.97%, 152 days), although this comparison is unadjusted; after adjustment, Medicaid patients were still associated with a significantly higher risk of mortality.

Policy changes provide a partial natural experiment. A multistate study found that expansion was also associated with a 19% relative increase in the odds of surgical resection, yet expansion narrowed geographic disparity in survival for patients in midsized and small metropolitan counties but did not improve income-related disparity. A Midwest study found a different pattern: the ACA did not significantly increase pancreatic surgery rates, and the authors concluded that insurance coverage alone is insufficient to increase receipt of surgical care. Geography matters because pancreatic surgery requires access to high-volume hospitals (HVH), often found in urban areas. Racial disparities interact with these factors; one analysis found that Black patients in expansion states with stage IV disease experienced a net increase in receipt of surgery following Medicaid expansion compared to patients in non-expansion states. Access to clinical trials and specialist multidisciplinary teams, which are concentrated in large centers, is generally assumed to follow the same pattern, but comparable quantitative data are less consistently available.

Open questions

Several questions remain unresolved. The first is how to detect cancer earlier, which is discussed in the screening section and depends on biomarkers that remain unvalidated for population use. The second concerns who would benefit from screening, since high-risk subgroups are not yet defined precisely enough to guarantee net benefit. The third concerns the microbiome and metabolism. Evidence suggests that microbiome-metabolism interactions are important contributors to therapy resistance in PDAC, extending traditional genome-centered models, but the picture is incomplete: the site-specific contributions of oral, gut, and intratumoral microbiota are still poorly defined. Even the best-documented association, between Pseudomonas and amino acid metabolism, has an uncertain direction; the authors note that whether this interaction is causal and the mechanisms underlying it remain unclear. Chemotherapy effects are also contested, as other research findings are inconclusive or contradictory, often due to variations in study design, patient populations, and microbiome analysis methods. Whether microbial changes cause tumors or follow from them is another open issue, since microbial composition is highly susceptible to environmental influences such as diet, antibiotic use, chronic inflammation, and nutritional status.

References

1. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinomancbi.nlm.nih.gov
2. Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?ncbi.nlm.nih.gov
3. Mixed acinar-neuroendocrine-ductal carcinoma of the pancreas: a tale of three lineages - PMCpmc.ncbi.nlm.nih.gov
4. Mixed pancreatic acinar cell-ductal adenocarcinoma: Complexities in diagnosis and treatment - ScienceDirectsciencedirect.com
5. Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Groupncbi.nlm.nih.gov
6. Clinical Characteristics of Resected Acinar Cell Carcinoma of the Pancreas: A Korean Multi-Institutional Studyncbi.nlm.nih.gov
7. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imagingncbi.nlm.nih.gov
8. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies - PMCpmc.ncbi.nlm.nih.gov
9. Biliary Obstruction due to a Pancreatic Plasmacytomancbi.nlm.nih.gov
10. Pancreatic Cancer Clinical Presentation: History, Physical Examinationemedicine.medscape.com
11. Rare pancreatic ductal adenocarcinoma variants and other malignant epithelial tumors: a comprehensive clinical and radiologic reviewncbi.nlm.nih.gov
12. Pancreatic Cancer in Younger Adults Is Expected to Rise Over the Coming Decadeseurekaen.substack.com
13. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017ncbi.nlm.nih.gov
14. The global, regional burden of pancreatic cancer and its attributable risk factors from 1990 to 2021link.springer.com
15. Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer - The ASCO Postascopost.com
16. Cause for concern: the rising incidence of early-onset pancreatic cancer - The Lancet Gastroenterology & Hepatologythelancet.com
17. Update on the global, regional, and national burden of pancreatic cancer: Insights from the Global Burden of Disease 2021 Study - PMCpmc.ncbi.nlm.nih.gov
18. Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021link.springer.com
19. The global, regional burden of pancreatic cancer and its attributable risk factors from 1990 to 2021 - PMCpmc.ncbi.nlm.nih.gov
20. Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019ncbi.nlm.nih.gov
21. The burden of pancreatic cancer in Latin America and the Caribbean: trends in incidence, mortality and DALYs from 1990 to 2019ncbi.nlm.nih.gov
22. Global surge in pancreatic cancer cases driven by ageing populations and modifiable risks — JOGHjogh.org
23. Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030ncbi.nlm.nih.gov
24. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 - The Lancet Gastroenterology & Hepatologythelancet.com
25. Global surge in pancreatic cancer cases driven by ageing populations and modifiable risks - PMCpmc.ncbi.nlm.nih.gov
26. Burden and future trajectory of pancreatic cancer in the EU-28, 1990-2023: A GBD 2023 analysis with projections to 2050 - PubMedpubmed.ncbi.nlm.nih.gov
27. Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030ncbi.nlm.nih.gov
28. Global, regional and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044ncbi.nlm.nih.gov
29. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4) - Annals of Oncologyannalsofoncology.org
30. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis - PubMedpubmed.ncbi.nlm.nih.gov
31. Effect of smoking cessation on the likelihood of pancreatitis and pancreatic cancerncbi.nlm.nih.gov
32. Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Areancbi.nlm.nih.gov
33. A meta-analysis of obesity and the risk of pancreatic cancerncbi.nlm.nih.gov
34. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies - PubMedpubmed.ncbi.nlm.nih.gov
35. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors - PMCpmc.ncbi.nlm.nih.gov
36. Prediabetes increases the risk of pancreatic cancer: A meta-analysis of longitudinal observational studies - PMCpmc.ncbi.nlm.nih.gov
37. Metabolic Dysfunction and Related Dietary Exposures in Relation to Pancreatic Cancer Risk: A Review of the Evidencedoi.org
38. Pancreatic cancer risk: causes and preventionroyalmarsden.nhs.uk
39. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose–Response Relationshipsaacrjournals.org
40. Pancreatitis: What It Is, Symptoms & Treatmentmy.clevelandclinic.org
41. Pancreatic Cancer Risk Factorshopkinsmedicine.org
42. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approachncbi.nlm.nih.gov
43. Risks and causes of pancreatic cancercancerresearchuk.org
44. Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical Perspectivecancernetwork.com
45. Pancreatic Cancer in Lynch Syndrome Patientsjcancer.org
46. Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management - PMCpmc.ncbi.nlm.nih.gov
47. Hereditary pancreatic cancer - ScienceDirectsciencedirect.com
48. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review - Gastroenterologygastrojournal.org
49. Pancreatic cancer — Knowledge Hubgenomicseducation.hee.nhs.uk
50. Pancreatic Cancer Genetic Mutationspancan.org
51. About Familial Pancreatic Cancer - Pancreatic Cancerpathology.jhu.edu
52. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort studyncbi.nlm.nih.gov
53. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center studyncbi.nlm.nih.gov
54. Is pancreatic cancer hereditary? 9 things to knowmdanderson.org
55. Screening for Pancreatic Cancer - PMC - NIHpmc.ncbi.nlm.nih.gov
56. Familial Pancreatic Cancer - PMCpmc.ncbi.nlm.nih.gov
57. Hereditary pancreatic cancers - Pancreatic Cancer UKpancreaticcancer.org.uk
58. Germline mutations in pancreatic cancer and potential new therapeutic options - PMCpmc.ncbi.nlm.nih.gov
59. Molecular characterization of early precursors of pancreatic ...docserv.uni-duesseldorf.de
60. Precursor lesions of pancreatic cancer - PubMedpubmed.ncbi.nlm.nih.gov
61. Significance of TP53, CDKN2A, SMAD4 and KRAS in ...pdfs.semanticscholar.org
62. JCI - KRAS: the Achilles’ heel of pancreas cancer biologyjci.org
63. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategiesnature.com
64. (PDF) Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancerresearchgate.net
65. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Canceraacrjournals.org
66. Pancreatic cancer stroma: an update on therapeutic targeting strategies - PMCpmc.ncbi.nlm.nih.gov
67. Frontiersfrontiersin.org
68. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtypenature.com
69. Frontiersfrontiersin.org
70. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancerncbi.nlm.nih.gov
71. Molecular Subtypes of Pancreatic Cancer: A Review of the Literature - PMCpmc.ncbi.nlm.nih.gov
72. Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma - PMCpmc.ncbi.nlm.nih.gov
73. Early neoplastic lesions of the pancreas: initiation, progression, and opportunities for precancer interception - PMCpmc.ncbi.nlm.nih.gov
74. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
75. Pancreatic cancer symptoms: Early detection and moremedicalnewstoday.com
76. Methods for the treatment of cancersimage-ppubs.uspto.gov
77. Symptoms of pancreatic cancercancerresearchuk.org
78. Pancreatic Cancer Signs & Symptomsmoffitt.org
79. ‘How I knew I had pancreatic cancer’: Survivors' symptomsmdanderson.org
80. Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancerclinicaltrials.gov
81. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging - PMCpmc.ncbi.nlm.nih.gov
82. CA19-9 as a Pancreatic Cancer Biomarker: Limitations and New Frontiers - Creative Biolabscreative-biolabs.com
83. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review - PubMedpubmed.ncbi.nlm.nih.gov
84. CA19-9 for detecting recurrence of pancreatic cancernature.com
85. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncologyjgo.amegroups.org
86. Defining Borderline Resectable Pancreatic Cancer: Emerging Consensus for an Old Challenge in: Journal of the National Comprehensive Cancer Network Volume 13 Issue 5 (2015)jnccn.org
87. Pancreatic Cancermdanderson.org
88. Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals - ScienceDirectsciencedirect.com
89. Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations - PMCpmc.ncbi.nlm.nih.gov
90. Pancreatic cancer screening in high-risk individuals with genetic susceptibility - PMCpmc.ncbi.nlm.nih.gov
91. Pancreatic Cancer: Screening and Early Detection - PubMedpubmed.ncbi.nlm.nih.gov
92. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer - PMCpmc.ncbi.nlm.nih.gov
93. Pancreatic Cystic Lesions in the Older Patient: A Review of Clinical Guidelines and Managementlink.springer.com
94. 96 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 91 • NUMBER 2 FEBRUARY 2024ccjm.org
95. Application of the 2024 International Association of Pancreatology Guidelines for Identifying (Pre)Malignancy Among Presumed Intraductal Papillary Mucinous Neoplasms via CT and MRI - ScienceDirectsciencedirect.com
96. Pancreatic cyst features predict future development of pancreatic cancer: results of a nested case-control study - Gastrointestinal Endoscopygiejournal.org
97. Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Featuresclinicaltrials.gov
98. Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancerncbi.nlm.nih.gov
99. Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancerncbi.nlm.nih.gov
100. Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer - PMCpmc.ncbi.nlm.nih.gov
101. Plasma cell-free DNA methylome as early detection and prognostic marker for pancreatic cancermedrxiv.org
102. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancerspnas.org
103. Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer - PMCpmc.ncbi.nlm.nih.gov
104. Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologistccjm.org
105. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer - PubMedpubmed.ncbi.nlm.nih.gov
106. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shiftncbi.nlm.nih.gov
107. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trialsncbi.nlm.nih.gov
108. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trialncbi.nlm.nih.gov
109. Gemcitabine/Nab-Paclitaxel vs Modified FOLFIRINOX in Metastatic Pancreatic Cancer - The ASCO Postascopost.com
110. Neoadjuvant strategies for pancreatic cancer - PubMedpubmed.ncbi.nlm.nih.gov
111. POLO Trial Shows Maintenance Olaparib Improves Progression-Free Survival in Metastatic Pancreatic Cancerascopost.com
112. Maintenance Olaparib vs Placebo in Germline <em>BRCA</em>-Mutated Metastatic Pancreatic Cancer: Overall Survival Analysis of the POLO Trialascopost.com
113. Treatment of pancreatic cancer—neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer - PMCpmc.ncbi.nlm.nih.gov
114. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysisnature.com
115. Modified FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer - The ASCO Postascopost.com
116. FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety - PubMedpubmed.ncbi.nlm.nih.gov
117. Real-world comparative effectiveness of FOLFIRINOX versus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer: prognostic impact of metastatic site and burden in a Middle Eastern cohort - PMCpmc.ncbi.nlm.nih.gov
118. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancernejm.org
119. Long‐Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutationsncbi.nlm.nih.gov
120. Survival Rates for Pancreatic Cancercancer.org
121. Pancreatic Cancer Survival Ratepancan.org
122. Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010nature.com
123. Palliation of malignant gastroduodenal obstruction: fluoroscopic metallic stent placement with different approaches - PMCpmc.ncbi.nlm.nih.gov
124. Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: Endoscopy or surgery? - ScienceDirectsciencedirect.com
125. Long Term Outcome of Biliary and Duodenal Stenting in Palliative Treatment of Patients with Unresectable Pancreatic Adenocarcinoma - Gastrointestinal Endoscopygiejournal.org
126. Gastroduodenal stenting - PubMedpubmed.ncbi.nlm.nih.gov
127. Combined biliary and duodenal stenting for palliation of pancreatic cancer: Scandinavian Journal of Gastroenterology: Vol 38, No 10tandfonline.com
128. Biliary obstruction and pancreatitis after duodenal stent placement in the descending duodenum: a retrospective studyncbi.nlm.nih.gov
129. The Daily Practice of Pancreatic Enzyme Replacement Therapy After Pancreatic Surgery: a Northern European Survey: Enzyme Replacement After Surgeryncbi.nlm.nih.gov
130. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer - PMCpmc.ncbi.nlm.nih.gov
131. Pancreatogenic Diabetes after Pancreatic Resection - ScienceDirectsciencedirect.com
132. Association between pancreatic fibrosis and development of pancreoprivic diabetes after pancreaticoduodenectomyncbi.nlm.nih.gov
133. Healthy eating and type 3c diabetes after surgery to remove pancreatic cancer - Pancreatic Cancer UKpancreaticcancer.org.uk
134. Population-Level Incidence and Predictors of Surgically Induced Diabetes and Exocrine Insufficiency after Partial Pancreatic Resection - PMCpmc.ncbi.nlm.nih.gov
135. Breaking the stromal barrier in pancreatic cancer: Advances and challenges - ScienceDirectsciencedirect.com
136. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancerncbi.nlm.nih.gov
137. Overcoming therapy resistance in pancreatic cancer: New insights and future directions - ScienceDirectsciencedirect.com
138. Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinomadoi.org
139. Nanomedicine breakthroughs overcoming pancreatic cancer drug resistance through precision nano-interventionsncbi.nlm.nih.gov
140. Targeting the Tumour Microenvironment in Pancreatic Cancer: From Stromal Reprogramming to Emerging Therapeuticsmdpi.com
141. Drug Delivery Strategies for the Treatment of Pancreatic Cancerncbi.nlm.nih.gov
142. Health Insurance Disparities in the Treatment of Pancreatic Cancer - ScienceDirectsciencedirect.com
143. Disparities in primary pancreatic adenocarcinoma survival by Medicaid-status: A national population-based risk analysis - PubMedpubmed.ncbi.nlm.nih.gov
144. Medicaid Expansion Timing and Pancreatic Cancer Resection Rates and Survival - PubMedpubmed.ncbi.nlm.nih.gov
145. Barriers beyond Medicaid: A Midwest study on pancreatic surgery access in the post-Affordable Care Act era - PubMedpubmed.ncbi.nlm.nih.gov
146. Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancerscancernetwork.com
147. New insights into microbiome metabolic mechanisms for pancreatic cancer therapy - ScienceDirectsciencedirect.com
148. Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis - PubMedpubmed.ncbi.nlm.nih.gov
149. Full article: Microbiome and pancreatic cancer: time to think about chemotherapytandfonline.com
150. Gut microbiota, circulating metabolites, and pancreatic cancer risk: a multi-method causal inference study with cross-population validation - PMCpmc.ncbi.nlm.nih.gov
151. Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma - PMCpmc.ncbi.nlm.nih.gov
152. Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysislink.springer.com